OVERVIEW
Patients with hormone receptor (HR)-positive metastatic breast cancer are regularly treated with a cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy. However, many patients' disease progresses and requires other treatment options. In this interactive virtual symposium, our expert faculty will highlight the recent clinical trial data updates in patients with HR-positive metastatic breast cancer, including estrogen receptor inhibition, PI3K/AKT/mTOR pathway inhibitors, and antibody-drug conjugates. Faculty will also discuss real-world patient cases and contextualize treatment options. Attendees will have the opportunity to engage through real-time polling, pre-post questions, and a Q&A session.
Enhance Your Virtual Experience With Backstage Pass!
Join our 30-minute post-symposium breakout session connecting the program speakers and audience in the virtual environment. Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video Encouraged*
GOAL STATEMENT
The goal of this activity is for learners to be better able to understand the changing treatment paradigm and future directions for HR-positive metastatic breast cancer.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [ITEM] Latest clinical data informing treatment decisions for HR-positive metastatic breast cancer (mBC) Have greater competence related to [ITEM] Offering tailored treatment for patients with HR-positive mBC Demonstrate greater confidence in their ability to [ITEM] Integrate novel therapies for HR-positive mBC into clinical practice
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO][MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [italic][bold]AMA PRA Category 1 Credits[/italic][/bold]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an independent educational grant from [bold]AstraZeneca[/bold].